Vident Investment Advisory, LLC Seagen Inc. Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $3,565 - $3,918	19 Added 0.5%	3,786 $728,000
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $163,060 - $259,536	-1,278 Reduced 25.33%	3,767 $762,000
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $32,746 - $38,828	279 Added 5.85%	5,045 $648,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $356,436 - $474,589	-2,635 Reduced 35.6%	4,766 $626,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $818,360 - $1.35 Million	-7,521 Reduced 50.4%	7,401 $1.31 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $33,131 - $43,724	277 Added 1.89%	14,922 $2.15 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $168,090 - $225,023	1,179 Added 8.76%	14,645 $2.27 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $48,432 - $57,738	340 Added 2.59%	13,466 $2.29 Million
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $122,382 - $145,956	906 Added 7.41%	13,126 $2.07 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $742,141 - $1.03 Million	5,397 Added 79.1%	12,220 $1.7 Million
Q4 2020 Feb 08, 2021	BUY	$164.63 - $211.93 $1.12 Million - $1.45 Million	6,823 New	6,823 $1.2 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.